Non-Receptor Tyrosine Kinase Inhibitors in Lung Cancer

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Non-Receptor Tyrosine Kinase Inhibitors in Lung Cancer

Anti-Cancer Agents in Medicinal Chemistry, 7(6): 633-642.

Author(s): Olwen Hahn and Ravi Salgia.

Affiliation: Section of Hematology, Oncology,University of Chicago Medical Center, Pritkzer School of Medicine,5841 S Maryland Ave, MC 2115, Chicago, Il 60637, USA.


Lung cancer is a leading cause of cancer death. Systemic therapies with cytotoxic chemotherapies remain ineffective. Current research efforts in lung cancer have focused on developing novel agents to target cellular pathways that are altered in lung cancer. Protein tyrosine kinases are a family of oncogenes that regulate important cellular processes such as differentiation, proliferation, cell cycle, motility, and apoptosis. In this article, we review non receptor tyrosine kinases ’ role in lung cancer and the development of agents that target these proteins.


Lung cancer, non receptor tyrosine kinase inhibitors, novel targets.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 7
Issue Number: 6
First Page: 633
Last Page: 642
Page Count: 10
DOI: 10.2174/187152007784111322
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science